Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis*

Resolvins are endogenous lipid mediators that actively regulate the resolution of acute inflammation. Resolvin E1 (RvE1; (5S,12R,18R)-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid) is an endogenous anti-inflammatory and pro-resolving mediator derived from eicosapentaenoic acid that regulates leukocyte migration and enhances macrophage phagocytosis of apoptotic neutrophils to resolve inflammation. In the inflammatory milieu, RvE1 mediates counter-regulatory actions initiated via specific G protein-coupled receptors. Here, we have identified RvE1-specific signaling pathways initiated by the RvE1 receptor ChemR23. RvE1 stimulated phosphorylation of Akt that was both ligand- and receptor-dependent. RvE1 regulated Akt phosphorylation in a time (0–15 min)- and dose-dependent (0.01–100 nm) manner in human ChemR23-transfected Chinese hamster ovary cells. RvE1 stimulated phosphorylation of both Akt and a 30-kDa protein, a downstream target of Akt, identified using a phospho-Akt substrate antibody. The 30-kDa protein was identified as ribosomal protein S6, a translational regulator, and its phosphorylation was inhibited by a phosphatidylinositol 3-kinase (PI3K) inhibitor (wortmannin) and an ERK inhibitor (PD98059) but not by a p38-MAPK inhibitor (SB203580). Ribosomal protein S6 is a downstream target of the PI3K/Akt signaling pathway as well as the Raf/ERK pathway. In ChemR23-expressing differentiated HL60 cells, RvE1 also stimulated the phosphorylation of ribosomal protein S6. In addition, RvE1 enhanced phagocytosis of zymosan A by human macrophages, which are inhibited by PD98059 and rapamycin (mTOR inhibitor). These results indicate that RvE1 initiates direct activation of ChemR23 and signals receptor-dependent phosphorylation. These phosphorylation-signaling pathways identified for RvE1 receptor-ligand interactions underscore the importance of endogenous pro-resolving agonists in resolving acute inflammation.

[1]  Takao Shimizu,et al.  Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. , 2009, Annual review of pharmacology and toxicology.

[2]  A. Kurosky,et al.  Lipoxin A4 Counterregulates GM-CSF Signaling in Eosinophilic Granulocytes1 , 2008, The Journal of Immunology.

[3]  D. Ganea,et al.  Bone Marrow-Derived Dendritic Cells Generated in the Presence of Resolvin E1 Induce Apoptosis of Activated CD4+ T Cells1 , 2008, The Journal of Immunology.

[4]  T. Yoshimura,et al.  Chemerin reveals its chimeric nature , 2008, The Journal of experimental medicine.

[5]  B. Levy,et al.  Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammation , 2008, Nature Immunology.

[6]  D. Greaves,et al.  Synthetic chemerin-derived peptides suppress inflammation through ChemR23 , 2008, The Journal of experimental medicine.

[7]  T. Ishizuka,et al.  Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. , 2008, Biochemical and biophysical research communications.

[8]  Yan Lu,et al.  Resolvin E1 Metabolome in Local Inactivation during Inflammation-Resolution1 , 2008, The Journal of Immunology.

[9]  K. Gronert Lipid autacoids in inflammation and injury responses: a matter of privilege. , 2008, Molecular interventions.

[10]  C. Serhan,et al.  Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  Lois E. H. Smith,et al.  Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis , 2007, Nature Medicine.

[12]  Charles N. Serhan,et al.  Resolvin E1 and protectin D1 activate inflammation-resolution programmes , 2007, Nature.

[13]  C. Serhan Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.

[14]  Charles N. Serhan,et al.  Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation1 , 2007, The Journal of Immunology.

[15]  J. Wallace,et al.  Resolution of in flammation: state of the art, definitions and terms , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  E. Butcher,et al.  Chemoattractants, extracellular proteases, and the integrated host defense response. , 2006, Experimental hematology.

[17]  B. Levy,et al.  RvE1 protects from local inflammation and osteoclastmediated bone destruction in periodontitis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  John Savill,et al.  Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.

[19]  Stuart Maudsley,et al.  The Origins of Diversity and Specificity in G Protein-Coupled Receptor Signaling , 2005, Journal of Pharmacology and Experimental Therapeutics.

[20]  Makoto Arita,et al.  Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Sher,et al.  Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1 , 2005, The Journal of experimental medicine.

[22]  Michael C. Ostrowski,et al.  The Serine/Threonine Kinase Akt Promotes Fcγ Receptor-mediated Phagocytosis in Murine Macrophages through the Activation of p70S6 Kinase* , 2004, Journal of Biological Chemistry.

[23]  Adriano G. Rossi,et al.  Inflammatory Resolution: new opportunities for drug discovery , 2004, Nature Reviews Drug Discovery.

[24]  C. Godson,et al.  Phagocytosis of apoptotic cells and the resolution of inflammation. , 2003, Biochimica et biophysica acta.

[25]  Q. Zhan,et al.  Protein phosphorylation in neutrophils monitored with phosphospecific antibodies. , 2003, Journal of immunological methods.

[26]  J. Melo,et al.  Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. , 2003, Cancer research.

[27]  C. Serhan,et al.  Resolvins , 2002, The Journal of experimental medicine.

[28]  C. Clish,et al.  Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing , 2000, The Journal of experimental medicine.

[29]  P. Cohen,et al.  Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase‐1 and p70 S6 kinase , 1996, FEBS letters.

[30]  A. Bøyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. , 1968 .

[31]  C. Mogensen The glomerular permeability determined by dextran clearance using Sephadex gel filtration. , 1968, Scandinavian journal of clinical and laboratory investigation.